Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
QT prolongation warrants cautious interpretation in proarrhythmic risk assessment; leaves open validation of heart rate-adjusted biomarkers.
Prolongation of the QT interval on the surface 12-lead electrocardiogram is widely accepted as a biomarker for the potential of a drug to produce torsades de pointes and/or sudden death. Detection of drug-induced prolongation of the QT interval in animals and man is frequently confounded by extrinsic and intrinsic factors that limit the ability to detect a true drug effect. In particular drugs that increase heart rate show an apparent increase in QT interval that confounds assessment of a true drug effect on cardiac ventricular repolarization. The basis for the use of the QT interval as a biomarker will be examined.
No takes yet. Share an insight, caveat, or question.
Gregory D. Sides (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: